First Capital Advisors Group’s Vaxcyte PCVX Stock Holding History

First Capital Advisors Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$4.99K	Buy	+100	New	+$4.74K	﹤0.01%	667

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Capital Advisors Group's PCVX Position: Q2 2023 in Review

First Capital Advisors Group opened a new position in Vaxcyte (PCVX) in Q2 2023: 100 shares worth $4.99K. The stake represents ﹤0.01% of the portfolio and ranks #667 among its holdings.

197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

First Capital Advisors Group held 100 shares of Vaxcyte worth $4.99K as of Q2 2023.
Vaxcyte was a new First Capital Advisors Group position in Q2 2023.
Vaxcyte made up ﹤0.01% of First Capital Advisors Group's portfolio in Q2 2023, its #667 holding.
197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.